Skip to main content

ImmunoGen Value Stock - Dividend - Research Selection

ImmunoGen

ISIN: US45253H1014, WKN: 878613

Market price date: 11.01.2021
Market price: 6,89 USD




ImmunoGen Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-03-2020
Cash flow
Net operating cash flow -88.367.000
Capital Expenditures -2.845.000
Free cash flow -91.212.000
Balance sheet
Total Equity -76.121.000
Liabilities & Shareholders equity 235.262.000
Income statement
Net income -104.133.000
Eps (diluted) -0,700
Diluted shares outstanding 148.761.000
Net sales/revenue 82.271.000

Fundamental ratios calculated on: 11-01-2021

Ratios
Key figures 11-01-2021
Cash flow
P/C -11,60
   
P/FC -11,24
Balance sheet
ROI-44,26
ROE-32,36
Income statement
P/E-9,84
Div. Yield0,00%
P/B-13,47
P/S12,46


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIMGN
Market Capitalization1.038.351.808,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.immunogen.com


Description of the company

ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.immunogen.com